Andon Health's low P/S ratio is due to poor revenue performance and negative growth forecast. Without top-line growth improvement, the P/S ratio could fall further. The market doesn't anticipate revenue improvement justifying a higher P/S ratio.
The trends in Andon Health's ROCE seem promising as it progresses from losses to profit, indicating good internal reinvestment. The 645% total return over the past five years points to high future performance expectations.
九安醫療股票討論區
很會賺錢的公司,爲啥股票價格不給力呢?
暫無評論